Analysis of immunization time, amplitude, and adverse events of seven different vaccines against SARS-CoV-2 across four different countries

Abstract

BackgroundScarce information exists in relation to the comparison of seroconversion and adverse events following immunization (AEFI) with different SARS-CoV-2 vaccines. Our aim was to correlate the magnitude of the antibody response to vaccination with previous clinical conditions and AEFI.MethodsA multicentric comparative study where SARS-CoV-2 spike 1-2 IgG antibodies IgG titers were measured at baseline, 21-28 days after the first and second dose (when applicable) of the following vaccines: BNT162b2 mRNA, mRNA-1273, Gam-COVID-Vac, Coronavac, ChAdOx1-S, Ad5-nCoV and Ad26.COV2. Mixed model and Poisson generalized linear models were performed.ResultsWe recruited 1867 individuals [52 (SD 16.8) years old, 52% men]. All vaccines enhanced anti-S1 and anti-S2 IgG antibodies over time (p<0.01). The highest increase after the first and second dose was observed in mRNA-1273 (p<0.001). There was an effect of previous SARS-CoV-2 infection; and an interaction of age with previous SARS-CoV-2 infection, Gam-COVID-Vac and ChAdOx1-S (p<0.01). There was a negative correlation of Severe or Systemic AEFI (AEs) of naïve SARS-CoV-2 subjects with age and sex (p<0.001); a positive interaction between the delta of antibodies with Gam-COVID-Vac (p=0.002). Coronavac, Gam-COVID-Vac and ChAdOx1-S had less AEs compared to BNT162b (p<0.01). mRNA-1273 had the highest number of AEFIs. The delta of the antibodies showed an association with AEFIs in previously infected individuals (p<0.001).ConclusionsThe magnitude of seroconversion is predicted by age, vaccine type and SARS-CoV-2 exposure. AEs are correlated with age, sex, and vaccine type. The delta of the antibody response only correlates with AEs in patients previously exposed to SARS-CoV-2.Registration numberClinicalTrials.gov, identifier NCT05228912.

Efficacy of Six Different SARS-CoV-2 Vaccines during a Six-Month Follow-Up and Five COVID-19 Waves in Brazil and Mexico

“…In all vaccine groups, SARS-CoV-2 Spike 1-2 IgG antibodies increased after the first to the second vaccination dose. mRNA-1273 and BNT162b2 developed the highest immune responses of all vaccines, in line with previous studies [14][15][16][17].…”

Effectiveness of different booster vaccine combinations against SARS-CoV-2 during a six-month follow-up in Mexico and Argentina

“…In relation to the humoral response following the administration of the booster vaccine, individuals with a history of infection either preceding the initiation of any vaccination or during the follow-up, displayed a markedly elevated overall antibody titer production. This finding aligns with multiple prior studies that have documented similar outcomes in the monitoring of vaccination regimens, suggesting a potentiation of the immune response generated initially after COVID-19 infection ( 22 , 30 ).…”

Antibody response to different COVID-19 vaccines among the migrant workers of Bangladesh

“…Consequently, we were unable to assess the participants’ long-term antibody response and safety profile. It is known that antibody level can vary based on sex ( 61 , 62 ); our limitation was that we had only male participants as only male migrant workers went through the Singapore outgoing pilot program during the study period. Another limitation was the small sample size in some categories, e.g., the single and booster dose recipients of different COVID-19 vaccines; and infected people within different vaccine types.…”